In vitro diagnostics point of care industry set for rapid growth
The worldwide in vitro medical diagnostic testing market was estimated to be $31.5 billion in 2008 (Complete Guide to the Diagnostic Market – Clinical Reports Pub 2007).
The in vitro diagnostics (IVD) market is segmented by the underlying technologies involved in performing the diagnostic tests. RapiPlex, our low-cost optical detection platform is most suited to the point of care (POC) segment of the market, particularly non-home/self testing.
Annual growth in this rapidly expanding area is predicted to continue in double digit figures between now and 2011 (Complete Guide to the Diagnostic Market – Clinical Reports Pub 2007).
Market demand
The demand for improved healthcare is being driven by governments eager to reduce costs and improve efficiencies, and by patients seeking prompt diagnosis. This in turn has led to an urgent need for new, rapid, cost-effective quantitative detection systems for the POC market.
Demand for these technologies will continue to grow in coming years, and RapiPlex with its rapid, accurate, multiple analyte detection is well positioned to meet this market need.
Meeting POC needs
RapiPlex meets all key needs of POC products including:
- Real-time diagnosis
- Improving efficiency including reduced waiting times
- Improving quality of treatment such as increased prescription efficiency and speed of treatment
- Ease of use and simplicity - RapiPlex is designed to be CLIA waivable, with a minimum number of user steps involved
- Price – RapiPlex’s ability to multiplex test for several analytes simultaneously from a single sample instead of individually reduces the overall cost per test to the end user